This finding makes the marker an interesting candidate with regard to FL treatment, because RHAMM has already been identified as a suitable target for cancer therapy, with low toxicity shown in clinical trials of RHAMM vaccination in other hematological malignancies [14,39,40,41]. The gene discussed is HMMR; the disease is hematologic disorder.